๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
Trackers Drugs Comparisons API
Trackers› Clinical trials› Waterford
Clinical trial register · Ireland

Clinical Trials in Waterford, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Ireland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Alert me on this filter Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 614 matching records held by the registry are in this view. Synced 25 Sep 2026, 03:15 UTC
614
Studies in scope
all four open statuses
320
Recruiting now
open to new participants
179
Lead sponsors
across recruiting studies
37
Irish site locations
across all listed studies
Phase mix of the 320 recruiting studies
Phase 3 96 Not applicable 79 Observational 76 Phase 2 29 Phase 1/2 20 Other 20
Narrow the register Reset
Matches title, registry number, sponsor, intervention and condition.
Recruitment status
Phase
Lead sponsor
Royal College of Surgeons, Ireland 4 Cancer Trials Ireland 4 National Cancer Institute (NCI) 3 AbbVie 3 AstraZeneca 2
Site location
Dublin 482 Cork 169 Galway 124 Limerick 56 Waterford 51
All 37 locations
Target enrolment
to

Trials with a site in Waterford

51 of 614 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Irish sites
Start
Recruiting
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
NCT07106632 Early Breast Cancer, Premenopausal Breast Cancer, HR+/HER2- Breast Cancer
UNICANCER
Phase 3
3,380
Cork, Dublin, Limerick, Tullamore, Waterford
2026-06-26
Recruiting
INSPIRE: INnovative SABR for Prostate Cancer All IREland
NCT07552168 Prostate Adenocarcinoma
Cancer Trials Ireland
Phase 2
136
Dublin, Cork, Waterford
2026-04-23
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer
NCT07218809 Epithelial Ovarian Cancer
DrugsMIRV·Torvutatug samrotecan·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin
AstraZeneca
Phase 3
1,100
Cork, Dublin, Waterford
2025-12-29
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779 Ovarian Cancer
DrugINCB123667
Incyte Corporation
Phase 3
466
Dublin, Galway, Waterford
2025-12-09
Not yet open
Frailty Intervention in Postoperative Hip Fracture Inpatients
NCT07027241 Hip Fractures (ICD-10 72.01-72.2), Frailty at Older Adults, Strength Training, Resistance Training
Royal College of Surgeons, Ireland
Not applicable
50
Waterford
2025-08-01
Recruiting
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438 Acute Myeloid Leukemia, Adult
DrugRevumenib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
448
Cork, Dublin, Galway, Waterford
2025-05-05
Recruiting
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression
NCT05784428 Oligometastatic Disease, Oligoprogression, Toxicity Due to Radiotherapy, Quality of Life
Robert Olson
Not applicable
598
Galway, Dublin, Cork, Waterford
2025-04-16
Recruiting
EXtubation Related Complications - the EXTUBE Study (EXTUBE)
NCT06442930 Extubation
University Health Network, Toronto
Observational
3,000
Castlebar, Cork, Dublin, Galway, Waterford
2025-04-14
Recruiting
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07032662 Chronic Inflammatory Demyelinating Polyneuropathy
Immunovant Sciences GmbH
Phase 2
162
Waterford
2025-03-18
Active, closed
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
NCT06680817 Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
DrugFaricimab
Hoffmann-La Roche
Observational
850
Dublin, Limerick, Waterford
2025-02-05
Recruiting
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
NCT06659549 Geographic Atrophy of the Macula
Galimedix Therapeutics Inc
Phase 2
110
Kildare, Waterford
2025-01-10
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101 Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Dublin, Galway, Waterford
2024-12-16
Active, closed
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824 PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
DrugsPembrolizumab·Paclitaxel
Genmab
Phase 3
191
Cork, Dublin, Limerick, Waterford
2024-11-25
Recruiting
Testing the Effectiveness of a Work Rehabilitation Intervention for Women with Breast Cancer
NCT06723899 Breast Cancer
University of Dublin, Trinity College
Not applicable
248
Galway, Waterford
2024-11-13
Recruiting
ENVELOP: Wound Care Following Pilonidal Sinus Surgery
NCT06647290 Pilonidal Sinus, Wound Healing
Royal College of Surgeons, Ireland
Not applicable
200
Castlebar, Dublin, Kilkenny, Limerick, Tullamore, Waterford
2024-10-01
Active, closed
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142 Immunoglobulin A Nephropathy
DrugPovetacicept
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Cork, Dublin, Galway, Waterford
2024-08-30
Recruiting
PINTA - Prophylactic Incisional Negative Pressure Therapy for Major Amputations
NCT06025253 Wound Surgical, Wound Infection, Cosmesis
Royal College of Surgeons, Ireland
Not applicable
728
Dublin, Galway, Limerick, Waterford
2024-03-01
Recruiting
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
NCT05512364 ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
DrugsElacestrant·Tamoxifen·Anastrozole·Exemestane
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
220
Dublin, Waterford
2023-12-15
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557 Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Anastrozole·Exemestane
AstraZeneca
Phase 3
5,511
Cork, Dublin, Galway, Waterford
2023-10-05
Active, closed
PROPEL-2: Prophylactic Negative Pressure Wound Therapy in Laparotomy Wounds
NCT05977816 Wound Surgical, Wound Infection, Cosmesis
Royal College of Surgeons, Ireland
Not applicable
2,000
Castlebar, Dublin, Galway, Letterkenny, Limerick, Sligo, Waterford
2023-07-14
Active, closed
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182 Hidradenitis Suppurativa
DrugUpadacitinib
AbbVie
Phase 3
1,328
Dublin, Cork, Galway, Waterford
2023-06-21
Active, closed
Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status
NCT05673187 NSCLC Stage IV, KRAS P.G12C
DrugAdagrasib
ETOP IBCSG Partners Foundation
Phase 2
68
Dublin, Limerick, Waterford
2023-06-12
Active, closed
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931 Endometrial Cancer
DrugSelinexor
Karyopharm Therapeutics Inc
Phase 3
257
Dublin, Cork, Galway, Waterford
2023-04-18
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778 Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
DrugsMirvetuximab Soravtansine·Bevacizumab
AbbVie
Phase 3
520
Dublin, Cork, Galway, Sligo, Waterford
2023-03-15
Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651 Colorectal Neoplasms
DrugsLevoleucovorin·Tucatinib·Leucovorin·Trastuzumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Cork, Dublin, Waterford
2022-10-24
Active, closed
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
NCT05587296 Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
Bayer
Phase 3
474
Galway, Dublin, Cork, Waterford
2022-10-14
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054 Breast Neoplasms
DrugsImlunestrant·Tamoxifen·Anastrozole·Exemestane
Eli Lilly and Company
Phase 3
8,000
Cork, Dublin, Galway, Sligo, Waterford
2022-10-04
Active, closed
Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma
NCT05123131 Multiple Myeloma
DrugsIsatuximab·Bortezomib·Lenalidomide·Dexamethasone
Cancer Trials Ireland
Phase 2
54
Dublin, Waterford
2022-04-01
Active, closed
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862 Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
DrugsZanubrutinib·Obinutuzumab·Lenalidomide·Rituximab
BeOne Medicines
Phase 3
799
Dublin, Waterford
2022-03-10
Active, closed
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493 Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Venetoclax·Rituximab
Loxo Oncology, Inc.
Phase 3
600
Dublin, Waterford
2021-09-20
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996 Early Breast Cancer
DrugGiredestrant
Hoffmann-La Roche
Phase 3
4,170
Cork, Dublin, Galway, Limerick, Waterford
2021-08-27
Recruiting
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
NCT04663750 Eye Diseases, Macular Degeneration, Wet, Sub-Macular Hemorrhage
King's College Hospital NHS Trust
Phase 3
210
Waterford
2021-04-16
Active, closed
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04608318 Chronic Lymphoid Leukemia
DrugsIbrutinib·Obinutuzumab·Venetoclax
German CLL Study Group
Phase 3
897
Cork, Dublin, Galway, Limerick, Waterford
2021-03-01
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596 Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsAdagrasib·Pembrolizumab
Mirati Therapeutics Inc.
Phase 2/3
626
Cork, Dublin, Galway, Limerick, Waterford
2020-12-02
Active, closed
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
NCT04595565 HER2-negative Breast Cancer, Triple Negative Breast Cancer
DrugsXeloda·Paraplatin·Sacituzumab Govitecan·Capecitabine
GBG Forschungs GmbH
Phase 3
1,332
Cork, Dublin, Limerick, Waterford
2020-10-28
Active, closed
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297 Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
DrugsBendamustine·Zanubrutinib·Rituximab
BeOne Medicines
Phase 3
510
Cork, Dublin, Galway, Limerick, Waterford
2019-08-20
Active, closed
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
NCT03924895 Urinary Bladder Cancer, Muscle-invasive
DrugsEnfortumab Vedotin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
595
Dublin, Waterford
2019-07-24
Active, closed
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
NCT03701334 Early Breast Cancer
DrugRibociclib
Novartis Pharmaceuticals
Phase 3
5,101
Wilton, County Limerick, Dublin, Waterford
2018-12-07
Active, closed
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318 Atopic Dermatitis
DrugUpadacitinib
AbbVie
Phase 3
1,533
Dublin, Cork, Waterford
2018-08-09
Active, closed
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246 Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
DrugsRucaparib·Nivolumab
pharmaand GmbH
Phase 3
1,097
Cork, Limerick, Waterford
2018-05-14
Recruiting
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02735707 Community-acquired Pneumonia, Influenza, COVID-19
DrugsAmoxicillin-clavulanate·Convalescent plasma·DMX-200·Interferon beta-1a
UMC Utrecht
Phase 3
20,000
Cork, Dublin, Galway, Waterford
2016-04-11
Active, closed
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT02506153 Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma
DrugsIpilimumab·Pembrolizumab
National Cancer Institute (NCI)
Phase 3
1,301
Dublin, Galway, Waterford
2015-11-10
Active, closed
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
NCT02804815 Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer
DrugAspirin
University College, London
Phase 3
11,000
Cork, Dublin, Galway, Limerick, Sligo, Waterford
2015-10
Active, closed
PALbociclib CoLlaborative Adjuvant Study
NCT02513394 Breast Cancer
DrugPalbociclib
Alliance Foundation Trials, LLC.
Phase 3
5,796
Cork, Dublin, Limerick, Sligo, Waterford
2015-08
Active, closed
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer
NCT02308085 Early Breast Cancer
ETOP IBCSG Partners Foundation
Not applicable
518
Dublin, Galway, Limerick, Waterford
2014-12-04
Active, closed
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
NCT02446405 Prostatic Neoplasms
DrugsLhrha·Enzalutamide
University of Sydney
Phase 3
1,125
Beaumont, Dublin, Galway, Tallaght, Waterford
2014-03
Active, closed
TAILORx Tissue Bank
NCT02050750 Breast Cancer
Cancer Trials Ireland
Observational
600
Cork, Donegal, Dublin, Galway, Limerick, Sligo, Waterford
2013-12
Recruiting
Breast Cancer Proteomics and Molecular Heterogeneity
NCT01840293 Primary Breast Cancer, Recurrent/Metastatic Breast Cancer
Cancer Trials Ireland
Observational
1,780
Cork, Dublin, Limerick, Waterford
2013-02
Active, closed
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
NCT01272037 Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma
DrugsTamoxifen Citrate·Anastrozole·Exemestane·Letrozole
National Cancer Institute (NCI)
Phase 3
5,018
Cork, Dublin, Mount Merrion, Galway, Limerick, Sligo, Waterford, Letterkenny
2011-02-28
Active, closed
Male Breast Cancer: Understanding the Biology for Improved Patient Care
NCT01101425 Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Observational
200
Cork, Dublin, Waterford
2010-12
Active, closed
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
NCT00310180 Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
DrugsTamoxifen Citrate·Anastrozole·Exemestane·Letrozole
National Cancer Institute (NCI)
Phase 3
10,273
Cork, Dublin, Mount Merrion, Galway, Limerick, Sligo, Waterford, Letterkenny
2006-04-07
Rows per page Showing 1–51 of 51
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Irish investigative site, filtered. Derived from ClinicalTrials.gov, U.S. National Library of Medicine. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-ireland/city/waterford

Query this register directly
GET /api/trials?country=ie&status=recruiting&phase=Phase+3&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Ireland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 614 studies in total at the last sync on 25 Sep 2026, 03:15 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 51 of those studies with a site in Waterford.

How many clinical trials are recruiting in Waterford?

19 of the 51 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:15 UTC sync. A further 1 have not yet opened recruitment, 31 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Waterford), 51 studies
PhaseStudiesRecruitingShare
Phase 333964.7%
Not applicable7413.7%
Observational529.8%
Phase 2539.8%
Phase 2/3112%

Most active sponsors

Lead sponsors with the most studies (Waterford)
Lead sponsorStudiesRecruiting
Cancer Trials Ireland42
Royal College of Surgeons, Ireland42
AbbVie30
National Cancer Institute (NCI)30
AstraZeneca21
BeOne Medicines20
ETOP IBCSG Partners Foundation20
European Organisation for Research and Treatment of Cancer - EORTC21
Hoffmann-La Roche20
Alliance Foundation Trials, LLC.10
Listing here is informational and not medical advice; eligibility is determined by each study team. Patients should discuss participation with their clinician. For trials across the wider EU, see the EU Clinical Trials Tracker.